High-Yield Resources on Use of & Access to COVID Antivirals

ACCESS TO FREE OR LOW-COST COVID ANTIVIRALS



PAXCESS Patient Support Program

Pfizer's Paxcess website, streamlined site for patients, pharmacists and providers that handles prior authorizations, checking patient's insurance coverage and figuring out each individual patient's path to free or low-cost access. Also allows patients, pharmacists or providers to enroll anyone in the U.S. government patient assistance program for **free or low-cost Paxlovid** (leveraging U.S. government-procured inventory).



Veklury

remdesiv

Merck Patient Assistance Program

Merck's Patient Assistance Program, enabling patients who could not otherwise afford it to access **molnupiravir** for free.

Veklury Patient Support and Services

Gilead's AdvancingAccess program to get **free or low-cost remdesivir for eligible outpatients** under a co-pay coupon program for commercially insured patients or a patient assistance program for uninsured patients. Includes insurance verification and collated financial support resources.

COVID TREATMENT GUIDELINES

Guidelines on the Treatment and Management of Patients With COVID-19

Treatment guidelines from IDSA, emphasizing that ambulatory patients with mild-to-moderate COVID-19 at high risk for progression to severe disease should receive nirmatrelvir/ritonavir initiated within five days of symptom onset, rather than no nirmatrelvir/ritonavir. Molnupiravir is suggested for those with no other treatment options.

RESOURCES ON HANDLING DRUG-DRUG INTERACTIONS

Management of Drug Interactions With Nirmatrelvir/Ritonavir (Paxlovid)

IDSA resource for clinicians on potential drug interactions.

PAXLOVID Patient Eligibility Screening Checklist Tool for Prescribers FDA checklist on patient eligibility for Paxlovid.

COVID-19 Drug Interactions

Tool from University of Liverpool for checking COVID-19 drug interactions.

Recommendations for the Management of Drug–Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications

NIH journal article on how to think about ritonavir-induced drug-drug interactions.

LINKS TO PUBLIC HEALTH RESOURCES

OHA COVID-19 Updates

Oregon public health department site collating useful COVID-19-related information.

COVID-19 Antiviral Treatment Screener

Screening tool from Ontario government that patients can use to determine whether they have high risk for disease progression and need treatment.

IHS Test to Treat Initiative

Indian Health Services website describing government programs available for obtaining free treatment and other services.

<u>Treatment of Respiratory Viruses</u> CDC advice on treating respiratory viruses like flu and COVID.

Respiratory Virus Guidance

CDC's current advice on respiratory viral isolation, with downloadable graphic.

COVID-19 Testing and Treatment

Patient-facing website from Ontario government with information about COVID-19 diagnostics and various treatment modalities.

RTLN LINKS

<u>Outpatient Roadmap</u> Paxlovid Point-of-Care Reference



© 2024. Infectious Diseases Society of America. Reprinted with permission.

This resource was funded in part by a cooperative agreement with the Centers for Disease Control and Prevention (grant number NU50CK000574). The Centers for Disease Control and Prevention is an agency within the Department of Health and Human Services (HHS). The contents of this resource do not necessarily represent the policy of CDC or HHS, and should not be considered an endorsement by the Federal Government.